Article

Six-gene signature predicts survival in advanced PCa

Researchers from Mount Sinai School of Medicine in New York say they have identified a six-gene signature that can be used in a test to predict survival in men with aggressive prostate cancer.

Related Videos
Jeffrey A. Albaugh, PhD, APRN, CUCNS, answers a question during a Zoom video interview
Amy M. Pearlman, MD, interviews Gia Ching on Zoom
1 expert is featured in this series.
Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
Wayne Kuang, MD, answers a question during a Zoom video interview
Related Content
Hackensack University Medical Center Launches Educational Website for People with Kidney Cancer
January 13th 2025

Hackensack University Medical Center Launches Educational Website for People with Kidney Cancer

The Kidney Cancer Resource Center is a collaborative effort by Hackensack Meridian Health’s leading experts in the field of renal cell carcinoma.
Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults
November 27th 2024

Episode 1 Podcast: Understanding Overactive Bladder (OAB): Pathophysiology, Diagnosis, and Management in Older Adults

Wayne Kuang, MD Bilal Chughtai, MD
Experts discuss overactive bladder and the impacts on quality of life, distinguishing OAB from BPH, and how a delayed diagnosis can worsen symptoms.
Enrollment goal met in trial of Urocross Expander Implant for BPH-related LUTS
January 13th 2025

Enrollment goal met in trial of Urocross Expander Implant for BPH-related LUTS

Hannah Clarke
The Expander-2 trial is intended to provide data that will support submission of the device for regulatory approval.
Former MLB player Dave Winfield shares lessons from baseball, philanthropy
November 15th 2024

Former MLB player Dave Winfield shares lessons from baseball, philanthropy

Urology Times staff
In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
FDA clears chemiluminescence-based immunoassay for free testosterone
January 10th 2025

FDA clears chemiluminescence-based immunoassay for free testosterone

Hannah Clarke
The test can provide results in 48 minutes to provide diagnostic insights for conditions such as hypogonadism, impotence, polycystic ovarian syndrome, and other androgenital syndromes.
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
January 10th 2025

CREST: Sasanlimab hits primary end point of EFS for NMIBC

Benjamin P. Saylor
Results from CREST will be presented at an upcoming medical conference.
© 2025 MJH Life Sciences

All rights reserved.